Maynard Um
-
-
-
-
-
-
-
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
-
-
-
-
-
-
-
Dermata Opens a New Chapter with the Release of Tome Skincare
-
-
-
-
-
-
-
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
-
-
-
-
-
-
-
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
-
-
-
-
-
-
-
Dermata's (DRMA) XYNGARI Phase 3 trial shows significant difference
-
-
-
-
-
-
-
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
-
-
-
-
-
-
-
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
-
433,990 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

